111 related articles for article (PubMed ID: 37579716)
21. Construction of a novel choline metabolism-related signature to predict prognosis, immune landscape, and chemotherapy response in colon adenocarcinoma.
Liu C; Liu D; Wang F; Liu Y; Xie J; Xie J; Xie Y
Front Immunol; 2022; 13():1038927. PubMed ID: 36451813
[TBL] [Abstract][Full Text] [Related]
22. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
23. Identification of CDT1 as a prognostic marker in human lung adenocarcinoma using bioinformatics approaches.
Jiang J; Zhang Y; Wang J; Yang X; Ren X; Huang H; Wang J; Lu J; Zhong Y; Lin Z; Lin X; Jia Y; Lin S
PeerJ; 2023; 11():e16166. PubMed ID: 37790630
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive analysis of immune-related gene signature based on ssGSEA algorithms in the prognosis and immune landscape of hepatocellular carcinoma.
Wang L; Wang L; He P
Front Genet; 2022; 13():1064432. PubMed ID: 36568383
[No Abstract] [Full Text] [Related]
25. Molecular identification of an immunity- and Ferroptosis-related gene signature in non-small cell lung Cancer.
Liu T; Luo H; Zhang J; Hu X; Zhang J
BMC Cancer; 2021 Jul; 21(1):783. PubMed ID: 34229636
[TBL] [Abstract][Full Text] [Related]
26. Identification and Prognostic Value Exploration of Radiotherapy Sensitivity-Associated Genes in Non-Small-Cell Lung Cancer.
Ma Q; Geng K; Xiao P; Zeng L
Biomed Res Int; 2021; 2021():5963868. PubMed ID: 34518802
[TBL] [Abstract][Full Text] [Related]
27. Deciphering a cell death-associated signature for predicting prognosis and response to immunotherapy in lung squamous cell carcinoma.
Mao G; Yang D; Liu B; Zhang Y; Ma S; Dai S; Wang G; Tang W; Lu H; Cai S; Zhu J; Yang H
Respir Res; 2023 Jul; 24(1):176. PubMed ID: 37415224
[TBL] [Abstract][Full Text] [Related]
28. Identification of specific prognostic markers for lung squamous cell carcinoma based on tumor progression, immune infiltration, and stem index.
Wu R; Ma R; Duan X; Zhang J; Li K; Yu L; Zhang M; Liu P; Wang C
Front Immunol; 2023; 14():1236444. PubMed ID: 37841237
[TBL] [Abstract][Full Text] [Related]
29. A Novel Hypoxia-Related Gene Signature with Strong Predicting Ability in Non-Small-Cell Lung Cancer Identified by Comprehensive Profiling.
Yang H; Wang Z; Gong L; Huang G; Chen D; Li X; Du F; Lin J; Yang X
Int J Genomics; 2022; 2022():8594658. PubMed ID: 35634481
[TBL] [Abstract][Full Text] [Related]
30. Construction of a prognostic model for non-small-cell lung cancer based on ferroptosis-related genes.
Han K; Wang J; Qian K; Zhao T; Liu X; Zhang Y
Biosci Rep; 2021 May; 41(5):. PubMed ID: 33988228
[TBL] [Abstract][Full Text] [Related]
31. Construction of a B cell-related gene pairs signature for predicting prognosis and immunotherapeutic response in non-small cell lung cancer.
Li X; Wang R; Wang S; Wang L; Yu J
Front Immunol; 2022; 13():989968. PubMed ID: 36389757
[TBL] [Abstract][Full Text] [Related]
32. Construction and validation of a two-gene signature based on SUMOylation regulatory genes in non-small cell lung cancer patients.
Sheng H; Hao Z; Zhu L; Zeng Y; He J
BMC Cancer; 2022 May; 22(1):572. PubMed ID: 35606717
[TBL] [Abstract][Full Text] [Related]
33. Identification of the ferroptosis-related long non-coding RNAs signature to improve the prognosis prediction and immunotherapy response in patients with NSCLC.
Li M; Zhang Y; Fan M; Ren H; Chen M; Shi P
BMC Med Genomics; 2021 Dec; 14(1):286. PubMed ID: 34861872
[TBL] [Abstract][Full Text] [Related]
34. Identification and validation of key genes with prognostic value in non-small-cell lung cancer via integrated bioinformatics analysis.
Wang L; Qu J; Liang Y; Zhao D; Rehman FU; Qin K; Zhang X
Thorac Cancer; 2020 Apr; 11(4):851-866. PubMed ID: 32059076
[TBL] [Abstract][Full Text] [Related]
35. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
Li B; Cui Y; Diehn M; Li R
JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive analyses of the heterogeneity and prognostic significance of tumor-infiltrating immune cells in non-small-cell lung cancer: Development and validation of an individualized prognostic model.
Pang Z; Chen X; Wang Y; Wang Y; Yan T; Wan J; Du J
Int Immunopharmacol; 2020 Sep; 86():106744. PubMed ID: 32623229
[TBL] [Abstract][Full Text] [Related]
37. Radiosensitization-Related Cuproptosis LncRNA Signature in Non-Small Cell Lung Cancer.
Xu Q; Liu T; Wang J
Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36360316
[TBL] [Abstract][Full Text] [Related]
38. A Comprehensive Bioinformatic Analysis for Identification of Myeloid-Associated Differentiation Marker as a Potential Negative Prognostic Biomarker in Non-Small-Cell Lung Cancer.
Zhou M; Chen Y; Gu X; Wang C
Pathol Oncol Res; 2022; 28():1610504. PubMed ID: 36061144
[No Abstract] [Full Text] [Related]
39. Analysis of expression differences of immune genes in non-small cell lung cancer based on TCGA and ImmPort data sets and the application of a prognostic model.
Sun L; Zhang Z; Yao Y; Li WY; Gu J
Ann Transl Med; 2020 Apr; 8(8):550. PubMed ID: 32411773
[TBL] [Abstract][Full Text] [Related]
40. Construction of a Novel LncRNA Signature Related to Genomic Instability to Predict the Prognosis and Immune Activity of Patients With Hepatocellular Carcinoma.
Zhu J; Huang Q; Liu S; Peng X; Xue J; Feng T; Huang W; Chen Z; Lai K; Ji Y; Wang M; Yuan R
Front Immunol; 2022; 13():856186. PubMed ID: 35479067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
